Dr. Thomas Atkinson is a trained psychometrician and outcomes researcher with expertise in quantitative and qualitative methodology. He serves as the Head of the MSKCC Behavioral Research Methods Core Facilities. Dr. Atkinson’s current line of independent research focuses on the exploration of the psychometric properties of existing patient reported outcomes (PRO) measures for the purposes of evaluating their use for inclusion in clinical trials and regulatory review. Dr. Atkinson has recently published two papers on the validity of pain measures with respect to recommendations put forth by the Food and Drug Administration, and has presented this work at multiple international conferences. As a Guest Worker at the FDA over the past two years, he has coauthored presentations with FDA colleagues on their perspectives regarding the measurement of pain palliation.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Thomas Atkinson discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures